Floatz logo

Carboplatin

Recurrent Childhood Acute Lymphoblastic Leukemia

Roswell Park Cancer InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Recurrent Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
PEGASPARGASE
University of Chicago
Phase 3BBB

View all 45 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →